News
Back to News

FDA Approves Lenvatinib/Everolimus for Advanced RCC

Robert J. Motzer, MD

Robert J. Motzer, MD

The FDA has approved the combination of lenvatinib (Lenvima) and everolimus (Afinitor) as a treatment for patients with advanced renal cell carcinoma (RCC) following prior antiangiogeneic therapy, based on progression-free survival (PFS) and overall survival (OS) data from a phase II study.

In the trial, known as Study 205, the combination of lenvatinib and everolimus reduced the risk of progression or death by 63% compared with the mTOR inhibitor everolimus alone. Median progression-free survival (PFS) with the combination was 14.6 versus 5.5 months with everolimus (HR, 0.37; 95% CI, 0.22-0.62). There was a 33% reduction in the risk of death with the combination versus the single-agent everolimus.

Prior to the approval, the combination of lenvatinib and everolimus had received a breakthrough therapy designation as a treatment for RCC. The combination was approved earlier than anticipated, under the FDA's priority review program. Click here to read the full article at OncLive.com




Back to News


Calendar of Events
SUNMONTUESWEDTHURSFRISAT
    123
45678910
11121314151617
18192021222324
25262728293031
Filter By